New Zealand markets closed

Charles River Laboratories International, Inc. (CRL)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
238.94-6.02 (-2.46%)
At close: 04:00PM EST
238.94 0.00 (0.00%)
After hours: 04:41PM EST
Full screen
Trade prices are not sourced from all markets
Previous close244.96
Open242.86
Bid0.00 x 800
Ask0.00 x 800
Day's range235.75 - 243.94
52-week range161.65 - 248.67
Volume714,159
Avg. volume531,540
Market cap12.27B
Beta (5Y monthly)1.38
PE ratio (TTM)25.92
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

    WILMINGTON, Mass., February 20, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support d

  • Business Wire

    Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance

    WILMINGTON, Mass., February 14, 2024--Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance

  • Business Wire

    Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test

    WILMINGTON, Mass., January 29, 2024--Building upon its flagship Endosafe® cartridge technology, Charles River Laboratories International, Inc. (NYSE: CRL) has advanced this innovation one step further and combined it with their recombinant cascade reagent (rCR) to launch the Endosafe® Trillium™ rCR cartridge offering. Expanding its robust bacterial endotoxin testing (BET) portfolio with a new animal-free testing solution, this offering, which builds on Charles River’s existing Trillium rCR vial